Clonidine
| Clonidine | |
|---|---|
| Salts [] | |
|---|---|
| Clonidine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 230.09 g/mol [1] |
| Appearance | Crystals [1] |
| Melting point | 130 [1] |
| Decomposition | When heated to decomposition it emits toxic fumes of nitroxides and /hydrogen chloride/. /Clonidine hydrochloride/ [1] |
| Solubility | Insoluble in water [1] |
| Predicted LogP | 1.6 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C9H9Cl2N3 |
| IUPAC name | N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine |
| SMILES | C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl |
| InChI | InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14) |
| InChIKey | GJSURZIOUXUGAL-UHFFFAOYSA-N |
| CAS number | 4205-90-7 |
| UNII | MN3L5RMN02 |
| PubChem CID | 2803 |
| Pharmacokinetics[] | |
|---|---|
| Onset | IR: 30–60 minutes after an oral dose |
| Elimination half-life | IR: 12–16 hours; 41 hours in kidney failure, 48 hours for repeated dosing |
| Duration of action | 4–8 hours[3] |
| Metabolism | Liver to inactive metabolites, 2/3 CYP2D6[4] |
| Excretion | Urine (72%)[5] |
| Routes of administration | Oral, epidural, intravenous, transdermal, topical |
| Dependence liability | Psychological: Low, Physical: High[6] |
| Toxicity [] | |
|---|---|
| LD50 | Rat: - oral: 126 mg/kg /Clonidine - ip: 100 mg/kg /Clonidine - iv: 29 mg/kg /Clonidine - sc: 77 mg/kg /Clonidine - oral: 150 mg/kg [1] |
| Dosing[] |
|---|
| Oral [] | |
|---|---|
| Light | ≤ 0.1 mg(5x - 71.4%) |
| Common | 0.1 mg |
| Strong | 0.1 - 0.2 mg |
| Heavy | 0.2 mg(2x - 28.6%) |
| Extreme | 0.2 mg + |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Clonidine (also known as Clonidin, Chlornidinum, Catapres-TTS, Catapresan, Catapressan, Clonidina, St-155-bs, St 155bs, Catapres-tts-1 or Catapres-tts-2) is a substance of the aniline class.
Chemistry
Salts []
Stereochemistry []
Clonidine is achiral.
Druglikeness
Lipinski's rule of five
Clonidine matches Lipinski's rule of five.Pharmacology
ATC Classification
- cardiovascular system (C)
- antihypertensives (C02)
- antiadrenergic agents, centrally acting (C02A)
- imidazoline receptor agonists (C02AC)
- (C02AC01)
- clonidine (C02AC01)
- nervous system (N)
- analgesics (N02)
- antimigraine preparations (N02C)
- other antimigraine preparations (N02CX)
- clonidine (N02CX02)
- sensory organs (S)
- ophthalmologicals (S01)
- antiglaucoma preparations and miotics (S01E)
- sympathomimetics in glaucoma therapy (S01EA)
- clonidine (S01EA04)
MeSH Classification
- analgesics (M0001067)
- antihypertensive agents (M0001456)
- sympatholytics (M0020945)
- adrenergic alpha-2 receptor agonists (M0543921)
Mechanism of action []
Clonidine is primarily an alpha-2 adrenoceptor agonist which causes central hypotensive and anti-arrhythmogenic effects. The alpha-2 adrenoceptor is coupled to the G-proteins G<sub>o</sub> and G<sub>i</sub>. G<sub>i</sub> inhibits adenylyl cyclase and activates opening of a potassium channel that causes hyperpolarization. Clonidine binding to the alpha-2 adrenoceptor causes structural changes in the alpha subunit of the G-protein, reducing its affinity for GDP. Magnesium catalyzes the replacement of GDP with GTP. The alpha subunit dissociates from the other subunits and associates with an effector. The stimulation of alpha-2 adrenoceptors in the locus coeruleus may be responsible for the hypnotic effects of clonidine as this region of the brain helps regulate wakefulness. Clonidine can also decrease transmission of pain signals at the spine. Finally clonidine can affect regulators of blood pressure in the ventromedial and rostral-ventrolateral areas of the medulla. [1]
Interactions []
Medical side effects []
172 side effects listed on drug labels in SIDER 4.1 (clonidine).
- Orthostatic hypotension
- Hypotension
- Confusional state
- Feeling abnormal
- Malaise
- Urinary tract infection
- Somnolence
- Drowsiness
- Dry mouth
- Asthenia
- Fatigue
- Nausea
- Abdominal pain upper
- Vomiting
- Upper respiratory tract infection
- Dizziness
- Syncope
- Nightmare
- Chest pain
- Hallucination
- Hyperhidrosis
- Tinnitus
- Irritability
- Nasal congestion
- Decreased appetite
- Anorexia
- Emotional disorder
- Oropharyngeal discomfort
- Oropharyngeal pain
- Headache
- Insomnia
- Body temperature increased
- Nasopharyngitis
- Rhinorrhoea
- Constipation
- Tachycardia
- Hypoxia
- Respiratory failure
- Hypoventilation
- Diarrhoea
- Ear pain
- Aggression
- Asthma
- Enuresis
- Thirst
- Tremor
- Crying
- Tearfulness
- Bradycardia
- Influenza like illness
- Abnormal sleep-related event
- Abdominal pain
- Gastrointestinal pain
- Epistaxis
- Sleep terror
- Pollakiuria
- Lower respiratory tract infection
- Otitis media acute
- Anxiety
- Dermatitis
- Rash
- Pain in extremity
- Viral diarrhoea
- Alopecia
- Angioedema
- Arrhythmia
- Arthralgia
- Musculoskeletal discomfort
- Atrioventricular block
- Mental disorder
- Breast disorder
- Colonic pseudo-obstruction
- Infection
- Cough
- Libido decreased
- Disturbance in sexual arousal
- Delirium
- Dental caries
- Depression
- Dermatitis contact
- Dyspnoea
- Oedema
- Endocrine disorder
- Excoriation
- Eye disorder
- Formication
- Gastrointestinal disorder
- Gynaecomastia
- Cardiac disorder
- Cardiac failure congestive
- Hepatitis
- Hyperaesthesia
- Hypersensitivity
- Muscle spasms
- Cramp muscle
- Lethargy
- Mediastinal disorder
- Meningitis
- Nervous system disorder
- Nervousness
- Tension
- Nocturia
- Pain
- Pallor
- Blanching
- Palpitations
- Paraesthesia
- Paresthesia of limbs
- Parotitis
- Pruritus
- Rhinitis
- Sick sinus syndrome
- Skin ulcer
- Sleep disorder
- Sneezing
- Cerebrovascular accident
- Withdrawal syndrome
- Shock
- Loss of consciousness
- Thrombocytopenia
- Erythema
- Urticaria
- Angiopathy
- Weight increased
- Bradyarrhythmia
- Urinary retention
- Sinus bradycardia
- Agitation
- Liver function test abnormal
- Electrocardiogram QT prolonged
- Accommodation disorder
- Skin hyperpigmentation
- Skin disorder
- Discomfort
- Ill-defined disorder
- Nasal dryness
- Hypoaesthesia
- Dry throat
- Salivary gland pain
- Lacrimation decreased
- Coombs test positive
- Dysuria
- Strangury
- Erectile dysfunction
- Dry eye
- Papule
- Vision blurred
- Abnormal dreams
- Rash maculo-papular
- Delusional perception
- Rash generalised
- Withdrawal hypertension
- Application site pain
- Application site burn
- Instillation site pain
- Application site rash
- Electrocardiogram abnormal
- Sexual dysfunction
- Bradyphrenia
- Blood glucose increased
- Hallucinations, mixed
- Nodal arrhythmia
- Application site erythema
- Rash macular
- Device related infection
- Application site papules
- Application site discolouration
- Ileus
- Sensitisation
- Application site erosion
- Breast enlargement
- Loss of libido
Indications
- Attention deficit/hyperactivity disorder
- End stage cancer
- Essential hypertension
- Flushing
- Forgetfulness
- Hyperkinesia
- Hypertension
- Hypertensive
- Hypertensive crisis
- Hypotensive
- Menopause
- Mental disorder
- Migraine
- Neoplasm malignant
- Neuralgia
- Pain
- Psychotic disorder
- Renal hypertension
- Vascular headache
- Visceral pain
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 2803, Clonidine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/2803
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Clonidine. UNII: MN3L5RMN02. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/MN3L5RMN02
Efron D, Coscini N. Pharmacological management of attention deficit hyperactivity disorder in children and adolescents. Australian Prescriber. 2025-10-14; 48(5):156–160. PMID 41164104. https://doi.org/10.18773/austprescr.2025.043
Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF. CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metabolism and Disposition. September 2010; 38(9):1393–1396. PMID 20570945. https://doi.org/10.1124/dmd.110.033878
clonidine (Rx) - Catapres, Catapres-TTS, more. Medscape Reference. 2026-08-07. http://reference.medscape.com/drug/catapres-tts-clonidine-342382
Geyskes GG, Boer P, Dorhout Mees EJ. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. British Journal of Clinical Pharmacology. January 1979; 7(1):55–62. PMID 760743. https://doi.org/10.1111/j.1365-2125.1979.tb00897.x
CATAPRES clonidine hydrochloride 150 microgram/1mL injection ampoule (17919). Therapeutic Goods Administration (TGA). 12 August 2022. https://www.tga.gov.au/resources/artg/17919
Catapres Product information. Health Canada. 30 March 2015. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1943
Product information. Health Canada. 22 October 2016. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4045
Summary of Product Characteristics (SmPC). Clonidine 25mcg Tablets BP. 2 October 2020. https://www.medicines.org.uk/emc/product/6538/smpc
Catapres-TTS-1- clonidine transdermal system patch; Catapres-TTS-2- clonidine transdermal system patch; Catapres-TTS-3- clonidine transdermal system patch. DailyMed. 25 March 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4a55825-7041-42f4-b3b2-dd7a25dbe793
Onyda Xr- clonidine hydrochloride suspension, extended release. DailyMed. 11 April 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a15c850-9da5-4bdc-a34d-7f740a6149b7
Duraclon- clonidine hydrochloride injection, solution. DailyMed. 17 March 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638
Javadin- clonidine hydrochloride oral solution. DailyMed. 24 October 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36d94f5-a30d-4997-b141-e79a4ea45ecf
Kapvay (clonidine hydrochloride) extended-release tablets, for oral use Initial U.S. Approval: 1974. DailyMed. https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=768167
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 06:05:52 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 06:05:48 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 06:05:48 |
| gsrs | ok | 2026-11-20 06:05:49 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014714) | 2026-11-20 06:05:48 |
| kegg | ok | 2026-11-20 06:05:51 |
| pubchem | ok | 2026-11-20 06:05:48 |
| missing (no r/tripreports posts mention it) | 2026-11-20 06:05:48 | |
| sider | ok | 2026-11-20 06:05:48 |
| structure | ok | 2026-11-20 06:05:48 |
| wikipedia | ok | 2026-11-20 06:05:48 |